江苏艾迪药业

Aidi Pharmaceutical is a China-based biopharmaceutical company focused on the development and commercialization of innovative drugs for the treatment of HIV/AIDS, inflammation, and oncology. The company's flagship products include Ainuovirine (ACC007), a non-nucleoside reverse transcriptase inhibitor (NNRTI), and Ainuomiti (ACC008), a single-tablet triple-drug regimen for HIV-1 infection. Aidi Pharmaceutical leverages its research and development capabilities to address unmet medical needs in the infectious disease space. The company is listed on the Shanghai Stock Exchange STAR Market and maintains a robust pipeline of small molecule candidates. In addition to its innovative drug pipeline, the company also produces human protein products such as Ulinastatin and Urokinase.